

## Datasheet: HCA360

**BATCH NUMBER 172956**

<b>Description:</b>	HUMAN ANTI DURVALUMAB
<b>Specificity:</b>	DURVALUMAB
<b>Format:</b>	Purified
<b>Product Type:</b>	Monoclonal Antibody
<b>Clone:</b>	AbD41313ia
<b>Isotype:</b>	IgG1
<b>Quantity:</b>	0.1 mg

## Product Details

### Applications

This product has been reported to work in the following applications. This information is derived from testing within our laboratories, peer-reviewed publications or personal communications from the originators. Please refer to references indicated for further information. For general protocol recommendations, please visit [www.bio-rad-antibodies.com/protocols](http://www.bio-rad-antibodies.com/protocols).

	Yes	No	Not Determined	Suggested Dilution
ELISA	▪			

Where this product has not been tested for use in a particular technique this does not necessarily exclude its use in such procedures. Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own system using appropriate negative/positive controls.

<b>Product Form</b>	Human IgG1 antibody (lambda light chain) selected from the HuCAL phage display library and expressed in a human cell line. This antibody is supplied as a liquid.
<b>Preparation</b>	Purified IgG prepared by affinity chromatography on Protein A
<b>Source</b>	HKB-11
<b>Buffer Solution</b>	Phosphate buffered saline
<b>Preservative Stabilisers</b>	0.09% Sodium Azide (NaN <sub>3</sub> )
<b>Approx. Protein Concentrations</b>	Antibody concentration 0.5 mg/ml
<b>Immunogen</b>	Durvalumab
<b>Specificity</b>	<b>Human Anti-Durvalumab Antibody, clone AbD41313ia</b> is a paratope specific, inhibitory

anti-idiotypic antibody (Type 1) that specifically recognizes the free human monoclonal antibody drug durvalumab. The antibody does not recognize free PD-L1 nor durvalumab in complex with PD-L1.

Clone AbD41313ia is a fully human recombinant monoclonal antibody with IgG1 isotype and can be used as a surrogate positive control or reference standard in an anti-drug antibody (ADA) assay. This antibody has a monovalent intrinsic affinity of 14 nM, and is one of two antibodies with different affinities offered for ADA assays.

#### [ADA bridging ELISA](#)

HCA360 may also be used as the detection antibody together with the Anti-Durvalumab monovalent Fab antibody [TZA004](#), as capture antibody in a pharmacokinetic (PK) assay to measure free durvalumab captured via immobilized PD-L1.

#### [PK bridging ELISA](#)

Durvalumab (Imfinzi) is a human IgG1/kappa antibody with allotype G1m3. The CH2 domain was engineered with three amino acid substitutions (L238F, L239E, P335S) to reduce the Fc-mediated effector functions to prevent depletion of PD-L1+ T-cells. It was first approved for previously treated patients with advanced bladder cancer. It was later approved for the treatment of unresectable stage 3 NSCLC (Non-Small Cell Lung Cancer) and ES-SCLC. Durvalumab binds to PD-L1 to block the interaction with the inhibitory T cell receptor PD-1. This blockade removes the suppression of T-cells that are specific for MHC-1-presented neoepitopes on tumor cells. Removal of this inhibitory signal leads to the release of granzymes and perforins by the activated T-cells, and finally to the destruction of the tumor cells.

#### [View a summary of all anti-durvalumab antibodies](#)

---

**Affinity**

The intrinsic affinity of the monovalent form of Human anti Durvalumab antibody, clone AbD41313ia is  $K_D = 14$  nM as measured by real time, label free molecular interaction analysis on immobilized Durvalumab.

---

**ELISA**

This product may be used in a direct or indirect ELISA or as a detection reagent for durvalumab in a PK bridging ELISA together with [TZA004](#) (AbD41327) as the capture reagent. It can also be used to develop and calibrate anti drug antibody (ADA) assays to measure the ADA response in patient sera together with [HCA359](#)

Protocol: [ADA bridging ELISA](#).

---

**Storage**

This product is shipped at ambient temperature. It is recommended to aliquot and store at -20°C on receipt. When thawed, aliquot the sample as needed. Keep aliquots at 2-8°C for short term use (up to 4 weeks) and store the remaining aliquots at -20°C.

Avoid repeated freezing and thawing as this may denature the antibody. Storage in frost-free freezers is not recommended.

---

<b>Guarantee</b>	12 months from date of despatch
<b>Acknowledgements</b>	This product and/or its use is covered by claims of U.S. patents, and/or pending U.S. and non-U.S. patent applications owned by or under license to Bio-Rad Laboratories, Inc. See <a href="http://bio-rad.com/en-us/trademarks">bio-rad.com/en-us/trademarks</a> for details. Imfinzi is a trademark of Medimmune/AstraZeneca using Abgenix's XenoMouse technology.
<b>Health And Safety Information</b>	Material Safety Datasheet documentation #10040 available at: <a href="https://www.bio-rad-antibodies.com/SDS/HCA360">https://www.bio-rad-antibodies.com/SDS/HCA360</a>
<b>Licensed Use</b>	For <i>in vitro</i> research purposes and for commercial applications for the provision of <i>in vitro</i> testing services to support preclinical and clinical drug development. Any re-sale in any form or any other commercial application needs a written agreement with Bio-Rad.
<b>Regulatory</b>	For research purposes only
<b>Technical Advice</b>	Recommended protocols and further information about HuCAL recombinant antibody technology can be found in the <a href="#">HuCAL Antibodies Technical Manual</a> .

## Related Products

### Recommended Useful Reagents

[HISPEC ASSAY DILUENT \(BUF049A\)](#)

[LYNX RAPID HRP ANTIBODY CONJUGATION KIT \(LNK002P\)](#)

[HUMAN ANTI DURVALUMAB \(HCA359\)](#)

### ELISA Matched Pair - Capture Antibody

[HUMAN ANTI DURVALUMAB \(TZA004\)](#)

**Product inquiries:** [www.bio-rad-antibodies.com/technical-support](http://www.bio-rad-antibodies.com/technical-support)

To find a batch/lot specific datasheet for this product, please use our online search tool at: [bio-rad-antibodies.com/datasheets](http://bio-rad-antibodies.com/datasheets)  
'M442066:250528'

Printed on 29 Jan 2026